Nuvo Research Inc.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Toronto Canada (1983)
Status: No NME R&D (1983)

Organization Overview

First Clinical Trial
2004
NCT00108992
First Marketed Drug
1986
diazepam (valium)
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

NUVO PHARM | NUVO PHARMS INC | Nuvo Research GmbH

Active Ingredients

Marketed Drugs (19)

acetaminophen (tylenol) (2016)

amphetamine (Adderall) (2017)

butalbital (fiornal) (2016)

caffeine (2016)

chlordiazepoxide (librium) (2020)

clidinium (quarzan) (2020)

dextroamphetamine (Dexedrine) (2017)

diazepam (valium) (1986)

diclofenac (voltaren) (2009)

dofetilide (tikosyn) (2022)

fenofibrate (fenoglide) (2019)

folic acid (2015)

hydroxyzine (vistaril) (2017)

naproxen (naprosyn) (2011)

oxycodone (oxycontin) (2016)

phentermine (wyamine) (2014)

polyethylene glycol 3350 (colyte) (2016)

sodium polystyrene sulfonate (kayexalate) (2014)

sulfasalazine (azulfidine) (2002)

Drugs in Phase 4 Trials (3)

Key: Nuvo Research Inc. (0) Acquired (3)

ethyl chloride (1 trial)

lidocaine (xylocaine) (20 trials)

tetracaine (pontocaine) (20 trials)

Drugs in Phase 3 Trials (4)

Key: Nuvo Research Inc. (1) Acquired (3)

diclofenac (voltaren) (2 trials)

fentanyl (Innovar) (4 trials)

ketoprofen (orudis) (3 trials)

wf10 (5 trials)

Drugs in Phase 2 Trials (2)

Key: Nuvo Research Inc. (1) Acquired (1)

sodium chloride (1 trial)

triamcinolone (kenalog) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 3)

Osteoarthritis, Knee (Phase 3)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Shoulder Impingement Syndrome (Phase 2)

Shoulder Pain (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 35
  • # of Trial APIs: 9